Companies: 10,795·Total market cap: $144.5T
Castle Biosciences, Inc.

Castle Biosciences, Inc.

CSTLNASDAQHealthcare● Active
$20.12
$-0.89(-4.24%)
Market Cap$610238634
P/E Ratio—
52W High$44.28
52W Low$14.59
PE RatioMarket CapForecast

Castle Biosciences, Inc. (CSTL) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cstl · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Castle Biosciences, Inc. (CSTL) measures how much investors pay for each dollar of the company's trailing earnings. CSTL's current PE ratio of N/A is calculated by dividing its stock price of $20.12 by its TTM earnings per share of -$0.43.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.93
Based on 5 analysts
EPS (TTM)
-$0.43
TTM · diluted EPS
PEG Ratio
0.47
Below 1.0 · Growth adjusted
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Castle Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2017 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 48.2x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Diagnostics & Research · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Castle Biosciences, Inc.
Castle Biosciences, Inc.You
CSTL
$610MN/A—-$0.43
AMN Healthcare Services, Inc.
AMN Healthcare Services, Inc.
AMN
$1.2BN/A—-$2.48
CareDx, Inc
CareDx, Inc
CDNA
$1.1BN/A—-$0.40
DarioHealth Corp.
DarioHealth Corp.
DRIO
$55MN/A—-$0.84
Embecta Corp.
Embecta Corp.
EMBC
$198M8.62x—$1.64
Evolent Health, Inc.
Evolent Health, Inc.
EVH
$524MN/A—-$4.68
Fulgent Genetics, Inc.
Fulgent Genetics, Inc.
FLGT
$520MN/A—-$1.97

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 9 of 9 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
—$-0.83—
2024-12-31
FY2024
40.57x$0.66—
2023-12-31
FY2023
—$-2.14—
2022-12-31
FY2022
—$-2.58—
2021-12-31
FY2021
—$-1.24—
2020-12-31
FY2020
—$-0.54—
2019-12-31
FY2019
55.91x$0.61—
2018-12-31
FY2018
—$-0.60—
2017-12-31
FY2017
—$-1.26—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Castle Biosciences, Inc. (CSTL) measures how much investors pay for each dollar of the company's trailing earnings. CSTL's current PE ratio of N/A is calculated by dividing its stock price of $20.12 by its TTM earnings per share of -$0.43.

PE Ratio = Stock Price ÷ EPS (TTM)
= $20.12 ÷ -$0.43 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.
Price historyFinancial statementsEarnings

Frequently asked questions

CSTL pe ratio · 6 questions

CSTL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $20.12 and TTM EPS of -$0.43. Data sourced from Financial Modeling Prep via CSTL's SEC 10-K and 10-Q filings.

CSTL PE ratioWhat is CSTL PE ratioCurrent PE ratio of CSTLCSTL PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Castle Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08